Exelixis, Inc. (EXEL) – Financial and Strategic SWOT Analysis Review

Date: 2015-06

“Exelixis, Inc. (EXEL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Exelixis, Inc. (Exelixis) is a biopharmaceutical company. It focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has two advanced product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; and Cobimetinib (GDC-0973/XL518), a potent, highly selective inhibitor of MEK. The company’s product pipeline includes GDC-0973 (XL518), a highly selective inhibitor of mitogen-activated protein kinase kinase(MEK); and XL888, highly potent, orally bioavailable ATP-competitive inhibitor of Heat Shock Protein 90 (HSP90). The company also undertakes the development of products through collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of various potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

The company seeks to advance the development and commercialization of cabozantinib towards those cancer indications through partnerships and agreements.

Exelixis, Inc. Key Recent Developments

Apr 30, 2015: Exelixis Announces First Quarter 2015 Financial Results and Provides Corporate Update
Feb 24, 2015: Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
Dec 17, 2013: Exelixis Announces Webcast of January 15 Presentation at the J.P. Morgan 32nd Annual Healthcare Conference
Nov 26, 2013: Exelixis Announces Webcast of December 3 Presentation at the 25th Annual Piper Jaffray Healthcare Conference
Nov 04, 2013: Exelixis Announces Webcast of November 12 Presentation at the Credit Suisse 2013 Healthcare Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company”


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample